ILMN - NASDAQ

Illumina, Inc.

ILMN·NASDAQ

$170.93

+5.2%

HealthcareMedical - Diagnostics & Research

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$25.86B

EPS5.4800

P/E Ratio31.19

Earnings Date07/30/2026

6.64B

Assets

3Y-46.0%

5Y-12.0%

10Y+55.0%

3.92B

Total Liabilities

3Y-31.0%

5Y+36.0%

10Y+99.0%

2.72B

Total Equity

15%

3Y-59.0%

5Y-42.0%

10Y+16.0%

Illumina, Inc. Funding & Solvency Profile

ILMN · NASDAQ

Current Assets

Cash & Cash Equivalents1.42B

Net Receivables854.00M

Inventory564.00M

Other Current Assets238.00M

Total Current Assets3 B

Non-Current Assets

Property, Plant & Equipment1.13B

Goodwill & Intangible Assets1.32B

Long-Term Investments0.00

Other Non-Current Assets449.00M

Total Non-Current Assets2 B

Total Assets

6.64B

Financial Health Analysis

Current Ratio

2.08x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.44x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

2 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

50% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Illumina, Inc. Balance Sheet

ILMN • NASDAQ

Illumina, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Jan 2023	Jan 2022	Jan 2021	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	1.4B	1.1B	1B	2B	1.2B	1.8B	2B	1.1B	1.2B	734.5M	768.8M	636.2M	711.6M	434M	303M	248.9M	144.6M	327M	174.9M	38.4M
Short-Term Investments	215M	93M	6M	26M	107M	1.7B	1.4B	2.4B	920M	824.2M	617.5M	702.2M	454M	916.2M	886.6M	645.3M	548.9M	313.1M	211.1M	92.4M
Cash & Short-Term Investments	1.6B	1.2B	1.1B	2B	1.3B	3.5B	3.4B	3.5B	2.1B	1.6B	1.4B	1.3B	1.2B	1.4B	1.2B	894.3M	693.5M	640.1M	386.1M	130.8M
Net Receivables	854M	751M	752M	688M	664M	487M	573M	514M	411M	381.3M	385.5M	289.5M	238.9M	215M	173.9M	165.6M	157.8M	133.3M	83.1M	40M
Accounts Receivables	854M	751M	752M	688M	664M	487M	573M	514M	411M	380.9M	384.9M	287.4M	237.7M	213.1M	171.2M	165.6M	157.8M	133.3M	83.1M	40M
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	386K	636K	2.1M	1.3M	1.9M	2.7M	0.0	0.0	0.0	0.0	0.0
Inventory	564M	547M	587M	568M	431M	372M	359M	386M	333M	300.2M	270.8M	191.1M	154.1M	158.7M	128.8M	142.2M	92.8M	73.4M	54M	20.2M
Prepaids	0.0	0.0	0.0	0.0	279M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.7M	0.0	0.0	17.5M	0.0	12.6M	0.0
Other Current Assets	238M	228M	216M	268M	0.0	152M	105M	78M	91M	77.9M	54.3M	70.6M	58.9M	30.5M	52.4M	56.3M	20M	18.2M	26.9M	2.8M
Total Current Assets	3.3B	2.7B	2.6B	3.6B	2.7B	4.5B	4.5B	4.5B	3B	2.3B	2.1B	1.9B	1.6B	1.8B	1.5B	1.3B	981.6M	864.9M	562.8M	193.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.1B	1.2B	1.6B	1.7B	1.7B	1.5B	1.4B	1.1B	931M	713.3M	342.7M	265.3M	202.7M	166.2M	143.5M	129.9M	117.2M	89.4M	46.3M	25.6M
Goodwill	1.1B	1.1B	2.5B	3.2B	7.1B	897M	824M	831M	771M	776M	752.6M	724.9M	723.1M	369.3M	321.9M	278.2M	213.5M	228.7M	228.7M	2.1M
Intangible Assets	210M	295M	3B	3.3B	3.3B	142M	145M	185M	175M	242.7M	273.6M	314.5M	331.2M	130.2M	106.5M	70M	43.8M	47.8M	58M	108K
Goodwill & Intangible Assets	1.3B	1.4B	5.5B	6.5B	10.4B	1B	969M	1B	946M	1B	1B	1B	1.1B	499.5M	428.3M	348.2M	257.2M	276.5M	286.7M	2.2M
Long-Term Investments	0.0	227M	196M	211M	213M	418M	283M	260M	266M	57.4M	56.6M	37.2M	22.1M	0.0	45.3M	32M	0.0	55.9M	0.0	67.8M
Tax Assets	454M	567M	0.0	0.0	0.0	20M	64M	70M	88M	123.3M	134.5M	49.8M	88.5M	40.2M	19.7M	39.5M	47.4M	78.3M	80.2M	0.0
Other Non-Current Assets	449M	121M	217M	212M	232M	171M	105M	48M	46M	49.8M	30.9M	58.3M	34M	73.2M	14.4M	31.1M	26.5M	12M	11.8M	11.2M
Total Non-Current Assets	3.4B	3.6B	7.5B	8.7B	12.5B	3.1B	2.9B	2.5B	2.3B	2B	1.6B	1.4B	1.4B	779M	651.2M	580.7M	448.3M	512.2M	425M	106.9M
Total Assets	6.6B	6.3B	10.1B	12.3B	15.2B	7.6B	7.3B	7B	5.3B	4.3B	3.7B	3.3B	3B	2.6B	2.2B	1.8B	1.4B	1.4B	987.7M	300.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	347M	322M	324M	390M	430M	260M	235M	266M	210M	170M	183.4M	121.6M	104.1M	88.7M	69.1M	80M	52.8M	38.7M	24.3M	11.7M
Accounts Payable	240M	221M	245M	293M	332M	192M	149M	184M	160M	138M	139.2M	82.6M	73.7M	65.7M	49.8M	66.7M	52.8M	29.2M	24.3M	9.9M
Other Payables	107M	101M	79M	97M	98M	68M	86M	82M	50M	32M	44.2M	38.9M	30.4M	23M	19.3M	13.3M	0.0	9.5M	0.0	1.8M
Accrued Expenses	142M	317M	685M	626M	117M	153M	154M	193M	177M	111.8M	120.7M	112.6M	82.7M	39.3M	52M	49.4M	98.3M	30.3M	43.3M	8.2M
Short Term Debt	499M	578M	0.0	1.2B	0.0	562M	45M	1.1B	10M	1.3M	74.9M	304.3M	29.3M	37M	0.0	311.6M	290.2M	400M	16K	63K
Capital Lease Obligations (Current)	78M	0.0	86M	76M	71M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	101M	79M	97M	98M	68M	86M	82M	50M	32M	44.2M	38.9M	30.4M	23M	19.3M	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	270M	260M	252M	245M	234M	186M	167M	175M	130M	120.6M	96.7M	75.3M	50.8M	69.6M	52.6M	45.9M	0.0	15.9M	7.5M	0.0
Other Current Liabilities	249M	70M	223M	188M	241M	83M	64M	63M	219M	301M	134.9M	108.4M	55.1M	70M	53.2M	47.7M	0.0	24.7M	90.5M	13.8M
Total Current Liabilities	1.6B	1.5B	1.6B	2.8B	1.1B	1.2B	665M	1.8B	746M	704.7M	610.5M	722.2M	322.1M	304.6M	237.6M	534.5M	441.2M	509.6M	165.7M	33.8M
NON-CURRENT LIABILITIES
Long Term Debt	1.5B	1.5B	1.5B	1.5B	1.7B	673M	1.1B	890M	1.2B	1B	1B	986.8M	839.6M	805.4M	813.1M	78.4M	0.0	0.0	400M	0.0
Deferred Revenue (Non-Current)	0.0	67M	0.0	0.0	0.0	44M	42M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3M	-80.2M	2.5M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	47.4M	0.0	80.2M	7M
Other Non-Current Liabilities	360M	272M	620M	649M	915M	259M	160M	359M	360M	214M	180.5M	167.9M	324.2M	137.5M	80.6M	28.5M	77.1M	16.6M	10.3M	10M
Total Non-Current Liabilities	2.3B	2.4B	2.8B	2.9B	3.4B	1.6B	2B	1.3B	1.7B	1.3B	1.2B	1.2B	1.2B	942.9M	883M	106.9M	124.5M	18.9M	410.3M	19.5M
Capital Lease Obligations	564M	554M	773M	820M	845M	671M	695M	269M	144M	222.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	3.9B	3.9B	4.4B	5.7B	4.5B	2.9B	2.7B	3.1B	2.3B	2B	1.8B	1.9B	1.5B	1.2B	1.1B	641.4M	565.7M	528.5M	576.1M	53.2M
SHAREHOLDERS' EQUITY
Treasury Stock	-4.7B	-3.9B	-3.8B	-3.8B	-3.7B	-3.8B	-3B	-2.6B	-2.3B	-2B	-1.7B	-1.3B	-1.2B	-1.2B	-1.1B	-541.6M	-497.5M	-322.4M	-251.6M	0.0
Common Stock	2M	2M	2M	2M	2M	2M	2M	2M	2M	1.9M	1.9M	1.8M	1.8M	1.7M	1.7M	1.5M	1.4M	1.4M	628K	469K
Additional Paid-In Capital	7.8B	7.5B	9.6B	9.2B	8.9B	3.8B	3.6B	3.3B	2.8B	2.7B	2.5B	2.2B	2.6B	2.4B	2.2B	1.9B	1.6B	1.5B	1B	340.2M
Retained Earnings	-392M	-1.2B	-19M	1.1B	5.5B	4.7B	4.1B	3.1B	2.3B	1.5B	1B	561.2M	207.9M	82.5M	-68.7M	-155.3M	-280.2M	-332.5M	-383M	-104.6M
Accumulated Other Comprehensive Income/Loss	-10M	22M	-1M	3M	17M	2M	5M	-1M	-1M	-1M	36K	-1.1M	1.2M	2.1M	2.1M	1.8M	2.8M	2.4M	1.3M	11.3M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	73.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	2.7B	2.4B	5.7B	6.6B	10.7B	4.7B	4.6B	3.8B	2.8B	2.3B	1.8B	1.5B	1.5B	1.3B	1.1B	1.2B	864.2M	848.6M	411.7M	247.3M
Total Equity	2.7B	2.4B	5.7B	6.6B	10.7B	4.7B	4.6B	3.9B	3.1B	2.3B	1.9B	1.5B	1.5B	1.3B	1.1B	1.2B	864.2M	848.6M	411.7M	247.3M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	87M	220M	73M	32.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	6.6B	6.3B	10.1B	12.3B	15.2B	7.6B	7.3B	7B	5.3B	4.3B	3.7B	3.3B	3B	2.6B	2.2B	1.8B	1.4B	1.4B	987.7M	300.6M
Total Investments	215M	320M	202M	237M	320M	2.1B	1.7B	2.6B	1.2B	881.6M	674.1M	739.4M	476.1M	916.2M	931.9M	677.3M	548.9M	369M	211.1M	160.2M
Total Debt	2.6B	2.6B	2.3B	3.6B	2.5B	1.9B	1.9B	2B	1.2B	1B	1.1B	1.3B	868.9M	842.4M	813.1M	390M	290.2M	400M	400M	63K
Net Debt	1.1B	1.5B	1.2B	1.5B	1.3B	96M	-161M	853M	-33M	314.5M	321.8M	654.9M	157.2M	408.4M	510.1M	141.1M	145.6M	73M	225.1M	-38.3M
Shares Outstanding	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000	152,800,000

SEC Filings

ILMN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 26, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 04, 2026	March 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 09, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 02, 2026	April 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 12, 2026	December 28, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 05, 2026	February 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 30, 2026	January 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 08, 2026	2026	View Filing

Showing 1 to 10 of 477 filings

Related Guides

Blog Categories

Continue your ILMN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.